Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force

JAMA - Journal of the American Medical Association

Volumn 316, Issue 19, 2016, Pages 2008-2024

  Chou, Roger ^a   Dana, Tracy ^a   Blazina, Ian ^a   Daeges, Monica ^a   Jeanne, Thomas L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DATA ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INFORMATION PROCESSING; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; UNITED STATES; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION; DYSLIPIDEMIAS; FEMALE; MALE; META ANALYSIS; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 85006165406     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.15629     Document Type: Review

References (72)

1. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38-48.
2. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
3. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383-390.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25, pt B):2889-2934.
5. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366(19): 1752-1755.
6. National Institutes of Health. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Circulation-2002-ATP-III-Final-Report-PDF-3143.pdf. 2002. Accessed September 22, 2016.
7. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-1765.
8. Lloyd-Jones DM, Goff D, Stone NJ. Statins, risk assessment, and the new American prevention guidelines. Lancet. 2014;383(9917):600-602.
9. Chou R, Dana T, Blazina I, DaegesM, Jeanne TL. Statins for Prevention of Cardiovascular Disease in Adults: Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05206-EF-2.
10. US Preventive Services Task Force. Draft Recommendation statement: statin use for the primary prevention of cardiovascular disease in adults: preventive medication. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement175/statin-use-in-adults-preventive-medication1. 2016. Accessed September 22, 2016.
11. US Preventive Services Task Force. Screening for Lipid Disorders in Adults: Recomendation Statement. Rockville (MD): Agency for Healthcare Research and Quality; 2008. AHRQ publication 08-05114-EF-2.
12. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. Rockville, MD: Agency for Healthcare Research and Quality; 2008. AHRQ publication 08-05118-EF.
13. US Preventive Services Task Force. Final research plan: lipid disorders in adults (cholesterol, dyslipidemia): screening. https://www.uspreventiveservicestaskforce.org/Page/Document/final-research-plan98/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening1. Accessed September 22, 2016.
14. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021-2031.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560.
16. Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-analysis of inconsistent effects: A time for change. Ann Intern Med. 2014; 160(4):267-270.
17. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry inmeta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
18. Furberg CD, Adams HP Jr, Applegate WB, et al; Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90(4):1679-1687.
19. Downs JR, Clearfield M,Weis S, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622.
20. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361 (9364):1149-1158.
21. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of coronary heart disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478-1485.
22. Chan KL, Teo K, Dumesnil JG, Ni A, TamJ; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121(2):306-314.
23. Beishuizen ED, van de ReeMA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2004;27(12): 2887-2892.
24. Bone HG, Kiel DP, Lindsay RS, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007;92(12):4671-4677.
25. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101(6):627-634.
26. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435): 685-696.
27. Heljić B, Velija-Asimi Z, Kulić M. The statins in prevention of coronary heart diseases in type 2 diabetics. Bosn J Basic Med Sci. 2009;9(1):71-76.
28. Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 2005; 178(2):387-397.
29. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
30. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92(7):1758-1764.
31. Nakamura H, Arakawa K, Itakura H, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): A prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163.
32. Crouse JR III, Raichlen JS, RileyWA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA. 2007;297(12):1344-1353.
33. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117 (11):823-829.
34. Asselbergs FW, Diercks GFH, Hillege HL, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
35. Shepherd J, Cobbe SM, Ford I, et al;West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
36. AlbertMA, Glynn RJ, Fonseca FAH, et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. 2011;162 (1):106-114.
37. Shepherd J. TheWest of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76(9):113C-117C.
38. Ridker PM, Rifai N, Clearfield M, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-1965.
39. Newman CB, Szarek M, Colhoun HM, et al; Cards Investigators. The safety and tolerability of atorvastatin 10mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res. 2008; 5(3):177-183.
40. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Drugs. 2004;64(suppl 2):43-60.
41. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841): 565-571.
42. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in theWest of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-362.
43. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
44. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58 (3):303-309.
45. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in theWomen's Health Initiative. Arch Intern Med. 2012;172(2):144-152.
46. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: ameta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
47. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1(1): CD004816.
48. Tonelli M, Lloyd A, Clement F, et al; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: ameta-analysis. CMAJ. 2011;183(16):E1189-E1202.
49. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB. Evidence Report: Managing High Blood Cholesterol in Adults-Systematic Evidence Review From the Cholesterol Expert Panel, 2013. Washington, DC: US Department of Health and Human Services; 2013.
50. Gotto AM Jr, Whitney E, Stein EA, et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur Heart J. 2000;21(19):1627-1633.
51. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: ameta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25(23):3462-3468.
52. Richardson K, Schoen M, French B, et al. Statins and cognitive function: A systematic review. Ann Intern Med. 2013;159(10):688-697.
53. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: ameta-analysis. JAMA. 2006;295(1):74-80.
54. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788-2797.
55. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21 (4):464-474.
56. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51.
57. Peeters G, Tett SE, Conaghan PG, Mishra GD, Dobson AJ. Is statin use associated with new joint-related symptoms, physical function, and quality of life? results from two population-based cohorts of women. Arthritis Care Res (Hoboken). 2015;67(1):13-20.
58. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580-1590.
59. Kostis JB, Dobrzynski JM. Prevention of cataracts by statins: ameta-analysis. J Cardiovasc Pharmacol Ther. 2014;19(2):191-200.
60. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: A review of recent evidence. Curr Opin Lipidol. 2011;22(6):460-466.
61. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: ameta-analysis. Diabetes Care. 2009;32(10):1924-1929.
62. Preiss D, Seshasai SR,Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: ameta-analysis. JAMA. 2011;305(24):2556-2564.
63. Dormuth CR, Filion KB, Paterson JM, et al; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348: g3244.
64. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
65. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360 (9346):1623-1630.
66. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
67. Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: A systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28(2):138-144.
68. Pham B, Klassen TP, Lawson ML, Moher D. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol. 2005;58(8):769-776.
69. Kavousi M, LeeningMJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416-1423.
70. DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4): 266-275.
71. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):496-507.
72. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25, pt B):2935-2959.